Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis

Status Completed

Clinical Trial Summary

This is an open-label, Phase II Clinical Trial of Aplidin® (plitidepsin) in Patients with Primary Myelofibrosis and post polycythemia vera/essential thrombocythemia (Post-PV/ET) Myelofibrosis.

Clinical Trial Description

This trial tries to assess response rate (ORR) of plitidepsin in patients with:

primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF). Besides, the study results will allow to evaluate the effect of plitidepsin on bone marrow (BM) or peripheral blood histology and to determine the quality of life (QoL) and symptoms or participant patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01149681
Study type	Interventional
Source	PharmaMar
Contact
Status	Completed
Phase	Phase 2
Start date	July 2010
Completion date	February 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02916979` - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG	Phase 1
Not yet recruiting	`NCT06345495` - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly	Phase 2
Terminated	`NCT04866056` - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.	Phase 1/Phase 2
Completed	`NCT02784496` - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis	Phase 2
Completed	`NCT00069680` - Genetic Analysis of Gray Platelet Syndrome
Active, not recruiting	`NCT04097821` - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients	Phase 1/Phase 2
Active, not recruiting	`NCT03289910` - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia	Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting	`NCT06397313` - RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis	Phase 2
Not yet recruiting	`NCT06024915` - A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets	Phase 1
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Completed	`NCT02910258` - Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00997386` - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States	Phase 2
Completed	`NCT00666549` - Research Tissue Bank
Terminated	`NCT00522990` - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias	Phase 1/Phase 2
Terminated	`NCT00393380` - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor	Phase 2
Completed	`NCT00606437` - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants	Phase 1
Active, not recruiting	`NCT03952039` - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib	Phase 3
Not yet recruiting	`NCT04709458` - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis	Phase 1